Diabetes Drug Comparison — GLP-1 and SGLT2 Side by Side
The two most talked-about modern diabetes drug classes, GLP-1 receptor agonists and SGLT2 inhibitors, lower glucose in very different ways and offer different extra benefits. Understanding how they compare on A1c, weight, heart and kidney protection, and side effects helps you have a sharper conversation with your clinician. All of these medicines are prescription only and clinician-supervised; this page is educational and does not recommend a specific drug for you.
How each class works
GLP-1 receptor agonists (such as semaglutide, dulaglutide, and liraglutide) mimic a gut hormone that boosts insulin release, slows stomach emptying, and reduces appetite. SGLT2 inhibitors (such as empagliflozin, dapagliflozin, and canagliflozin) act on the kidneys to remove excess glucose through the urine. Because the mechanisms differ, the two classes are sometimes used together.
Side-by-side comparison
| Feature | GLP-1 receptor agonists | SGLT2 inhibitors |
|---|---|---|
| A1c lowering | Strong | Moderate |
| Weight effect | Significant weight loss | Modest weight loss |
| Cardiovascular benefit | Shown in outcome trials | Shown in outcome trials |
| Kidney protection | Benefit shown for several agents | Strong, consistent benefit |
| Heart-failure benefit | Neutral to modest | Clear reduction in hospitalisation |
| Route | Injection (some oral) | Oral tablet |
| Common side effects | Nausea, other digestive effects | Genital yeast infection, dehydration |
| Hypoglycaemia risk alone | Low | Low |
Cardiovascular and kidney evidence
SGLT2 inhibitors have a robust record in cardiovascular and renal outcome trials, showing reductions in heart-failure hospitalisation and slowing of kidney disease progression across studies such as the EMPA-REG OUTCOME, CANVAS, DAPA-HF, and CREDENCE programmes. Because of this, the ADA Standards of Care in Diabetes (2025) prioritise them for people with heart failure or chronic kidney disease. GLP-1 agonists have their own cardiovascular outcome evidence and are favoured when reducing atherosclerotic cardiovascular risk and body weight is the priority.
Weight and A1c
GLP-1 agonists generally produce larger reductions in both A1c and body weight. The semaglutide STEP trials and the tirzepatide SURMOUNT trials (tirzepatide is a dual GIP/GLP-1 agonist) demonstrated substantial weight loss in their study populations, which is why this class is central to combined diabetes-and-obesity care. SGLT2 inhibitors lower A1c more modestly and produce smaller weight loss, but add heart and kidney protection in a convenient oral tablet.
Side effects and who each suits
- GLP-1 agonists often cause early nausea that usually settles as the dose is titrated slowly. Most are injections, though oral forms exist.
- SGLT2 inhibitors can cause genital yeast infections and dehydration, and carry a rare risk of diabetic ketoacidosis; good fluid intake and hygiene help.
- People with heart failure or kidney disease often benefit most from an SGLT2 inhibitor; people who need major weight loss and A1c reduction often benefit most from a GLP-1 agonist.
- The two classes can be combined for complementary benefits when a clinician decides it is appropriate.
Cost and access differences
Both classes are branded and can be expensive, but the picture is shifting. Some SGLT2 inhibitors are approaching or reaching generic availability, which will lower their price over time, while most GLP-1 agonists remain branded with no generic yet. Access can also be shaped by insurer prior-authorization rules, which frequently target GLP-1 drugs. If cost or coverage is a barrier, our medication-cost and prior-authorization guides explain the savings routes and appeal steps.
Starting, titrating, and monitoring
How each class is started differs, and knowing what to expect makes the first weeks easier. GLP-1 agonists are usually begun at a low dose and increased slowly over weeks, because gradual titration reduces the early nausea most people feel. SGLT2 inhibitors are typically started at a standard dose with less need for titration, but your clinician will check kidney function first and remind you to stay well hydrated. For both classes, monitoring continues after you start — glucose, kidney function, and how you feel — so the dose can be tuned. If you take insulin or a sulfonylurea alongside either class, those doses may be lowered to avoid low blood glucose.
Who might avoid each class
These medicines suit most people, but there are situations where a clinician steers away from one. GLP-1 agonists are generally avoided in people with certain rare thyroid tumour histories or a history of pancreatitis, and are paused around pregnancy. SGLT2 inhibitors may be less suitable for people prone to genital infections, significant dehydration, or a history of diabetic ketoacidosis. This is exactly why the choice is individualised and clinician-supervised rather than something to self-select.
Where these fit alongside metformin and insulin
Neither class necessarily replaces metformin, which remains a common foundation, and neither replaces insulin when the body genuinely needs it. Instead, GLP-1 agonists and SGLT2 inhibitors are often added to metformin, or chosen early when heart, kidney, or weight priorities justify it. In people already on insulin, adding one of these classes can improve control and sometimes allow the insulin dose to be reduced under supervision. The combinations are individualised and always clinician-directed.
How this fits your plan
Medication is one tool. Combined with structured lifestyle change, many people with type 2 diabetes lower their A1c enough that a clinician can reduce medication, and some reach remission (A1c under 6.5% for at least three months without glucose-lowering drugs, per ADA). Trials like DiRECT (Lancet, 2018) demonstrated remission is achievable for some through intensive lifestyle change. Results vary. Never start, stop, or switch any of these medicines on your own.
Frequently Asked Questions
Is a GLP-1 better than an SGLT2 inhibitor?
Neither is universally better. GLP-1 agonists win on weight and A1c; SGLT2 inhibitors win on heart-failure and kidney protection in a simple oral tablet. The right choice depends on your health profile.
Can I take both together?
Yes, clinicians sometimes prescribe both because their mechanisms and benefits complement each other. That decision is individualised and supervised.
Do these drugs cause low blood sugar?
On their own, both classes carry a low hypoglycaemia risk. The risk rises when they are combined with insulin or a sulfonylurea, which may need dose adjustment.
Are these medicines a cure?
No. They manage diabetes and can support remission alongside lifestyle change, but type 2 diabetes is not cured and type 1 diabetes always requires insulin.